EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Gamma

Ensembl ID : ENSCSEG00000017673
Gene Symbol: PIK3CG
1 Cross references
216 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSCSEG00000012083
Gene Symbol: PDE10A
3 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSCSEG00000018144
Gene Symbol: PDE3A
3 Cross references
203 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSCSEG00000013333
Gene Symbol: PDE3A
2 Cross references
186 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSCSEG00000010095
Gene Symbol: PDE3B
3 Cross references
204 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSCSEG00000020919
Gene Symbol: PDE4A
2 Cross references
180 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSCSEG00000021093
Gene Symbol: PDE4A
3 Cross references
187 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSCSEG00000017412
Gene Symbol: PDE4B
3 Cross references
226 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSCSEG00000014124
Gene Symbol: PDE4D
4 Cross references
221 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSCSEG00000016982
Gene Symbol: PDE4D
3 Cross references
221 Possible Orthologues:

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSCSEG00000004689
Gene Symbol: PDE5AB
1 Cross references
209 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSCSEG00000014778
Gene Symbol: PDE7A
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).